Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Pariglasgene brecaparvovec is an AAV8-based gene therapy indicated as an adjunct to nutritional management in patients 8 years and older with glycogen storage disease type Ia, delivering a functional G6PC gene to hepatocytes to restore glucose-6-phosphatase activity. Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase (G6Pase).
- Mechanism
- Curator reviewed · 3 references
Pariglasgene brecaparvovec-opnr is a non-replicating, recombinant adeno-associated virus serotype 8 (AAV8) based vector containing a codon-optimized, wild-type human glucose-6-phosphatase (G6PC) gene. The G6PC gene is under the control of native human G6PC promoter and enhancer elements. The vector delivers a copy of the gene to hepatocytes, resulting in the production of normally functioning glucose-6-phosphatase (G6Pase).
- Primary indication
- Pariglasgene brecaparvovec-opnr is indicated to reduce daily cornstarch intake as an adjunct to nutritional management in adult and pediatric patients 8 years of age and older with glycogen storage disease type Ia (GSDIa).Curator reviewed · 1 structured indication
- First approval
- United States, 2026
- Also known as
- Pariglasgene brecaparvovec-opnr
- Code names
- AAV8G6PASE · AAV8G6PC · DTX-401
- Brand names
- Genglycos Kit 15 - < 21 Kg
Resolves to
What you can answer from here — as of October 30, 2026
Which drugs share a target with Pariglasgene brecaparvovec, and which of those have an active Phase 3 trial?